Biohaven EBITDA 2016-2022 | BHVN
Biohaven ebitda from 2016 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Biohaven Annual EBITDA
(Millions of US $) |
| 2021 |
$-679 |
| 2020 |
$-636 |
| 2019 |
$-478 |
| 2018 |
$-220 |
| 2017 |
$-108 |
| 2016 |
$-61 |
| 2015 |
$-10 |
Biohaven Quarterly EBITDA
(Millions of US $) |
| 2022-09-30 |
$-76 |
| 2022-06-30 |
$-284 |
| 2022-03-31 |
$-49 |
| 2021-12-31 |
$-217 |
| 2021-09-30 |
$-66 |
| 2021-06-30 |
$-166 |
| 2021-03-31 |
$-231 |
| 2020-12-31 |
$-166 |
| 2020-09-30 |
$-160 |
| 2020-06-30 |
$-159 |
| 2020-03-31 |
$-151 |
| 2019-12-31 |
$-135 |
| 2019-09-30 |
$-90 |
| 2019-06-30 |
$-199 |
| 2019-03-31 |
$-54 |
| 2018-12-31 |
$-48 |
| 2018-09-30 |
$-55 |
| 2018-06-30 |
$-38 |
| 2018-03-31 |
$-83 |
| 2017-12-31 |
$-28 |
| 2017-09-30 |
$-40 |
| 2017-06-30 |
$-25 |
| 2017-03-31 |
$-14 |
| 2016-12-31 |
$-23 |
| 2016-09-30 |
$-28 |
| 2016-06-30 |
$-7 |
| 2016-03-31 |
$-3 |
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.240B |
$0.463B |
|
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
|
